循環器ジャーナル71巻2号

2023年04月発行

特集 今だからこそ聞きたい心不全診療のこと。 Ⅲ．治療

新規心不全薬を，いつ，どの順序で使うべきか？

著者： 藤木伸也¹

所属機関： ¹新潟大学大学院医歯学総合研究科循環器内科学

ページ範囲：P.234 - P.243

POINT
・近年，複数の新規心不全薬が処方可能になり，適切な使用方法が問われている．

参考文献

1）McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014 ; 371 : 993-1004.

2）Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med 2019 ; 381 : 1609-20.

3）Tsutsui H, Momomura SI, Saito Y, et al. Efficacy and Safety of Sacubitril/Valsartan in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction-Results From the PARALLEL-HF Study. Circ J 2021 ; 85 : 584-94.

4）Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015 ; 373 : 2117-28.

5）Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017 ; 377 : 644-57.

6）Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2019 ; 380 : 347-57.

7）Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. N Engl J Med 2020 ; 383 : 1425-35.

8）Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med 2021 ; 384 : 117-28.

9）McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2019 ; 381 : 1995-2008.

10）Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med 2020 ; 383 : 1413-24.

11）Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med 2021 ; 385 : 1451-61.

12）Fox K, Ford I, Steg PG, et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction（BEAUTIFUL） : a randomised, double-blind, placebo-controlled trial. Lancet 2008 ; 372 : 807-16.

13）Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure（SHIFT） : a randomised placebo-controlled study. Lancet 2010 ; 376 : 875-85.

14）Tsutsui H, Momomura SI, Yamashina A, et al. Efficacy and Safety of Ivabradine in Japanese Patients With Chronic Heart Failure-J-SHIFT Study. Circ J 2019 ; 83 : 2049-60.

15）Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2020 ; 382 : 1883-93.

16）McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021 ; 42 : 3599-726.

17）Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure : A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2022 ; 79 : e263-421.

18）Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med 2019 ; 380 : 539-48.

19）Wachter R, Senni M, Belohlavek J, et al. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge : primary results of the randomised TRANSITION study. Eur J Heart Fail 2019 ; 21 : 998-1007.

20）Fried TR, Tinetti ME, Iannone L, et al. Health outcome prioritization as a tool for decision making among older persons with multiple chronic conditions. Arch Intern Med 2011 ; 171 : 1854-6.